Publications

Detailed Information

Effect of dutasteride on the expression of hypoxia-inducible factor-1α, vascular endothelial growth factor and microvessel density in rat and human prostate tissue

DC Field Value Language
dc.contributor.authorKu, Ja Hyeon-
dc.contributor.authorShin, Jung Ki-
dc.contributor.authorCho, Min Chul-
dc.contributor.authorMyung, Jae Kyung-
dc.contributor.authorPaick, Jae-Seung-
dc.contributor.authorMoon, Kyung Chul-
dc.date.accessioned2012-06-04T00:57:30Z-
dc.date.available2012-06-04T00:57:30Z-
dc.date.issued2009-
dc.identifier.citationSCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY; Vol.43 6; 445-453ko_KR
dc.identifier.issn0036-5599-
dc.identifier.urihttps://hdl.handle.net/10371/76742-
dc.description.abstractObjective. To evaluate the effects of dutasteride on the expression of angiogenesis markers in rat and human prostates. Material and methods. Eight-week-old male Sprague-Dawley rats were divided into three groups of six each according to dutasteride dose, including the control group (regular diet), 2.5 mg group (2.5 mg/kg dutasteride) and 5.0 mg group (5.0 mg/kg dutasteride). A total of 41 patients awaiting transurethral resection of the prostate (TURP) were divided into two groups: 20 patients received no medication and 21 received 0.5 mg dutasteride daily for 2-4 weeks until TURP. Results. At 2 weeks, dutasteride effected a significant decrease in body weight and prostate weight compared with the control rat group. Analysis by reverse transcription-polymerase chain reaction and Western blot revealed that hypoxia-inducible factor-1 alpha (HIF-1 alpha) and vascular endothelial growth factor (VEGF) expression was lower in the dutasteride-treated groups than in the control group, except for HIF-1 alpha protein. HIF-1 alpha and VEGF expression was similar in the 2.5 mg and 5.0 mg groups. Human prostate tissues demonstrated homogeneous staining of HIF-1 alpha and VEGF with regard to extent, intensity and intracellular location in both groups. There was no significant difference in microvessel density between the two groups. Conclusions. The expression of HIF-1 alpha and VEGF in rat prostates is suppressed by dutasteride. However, less than 4 weeks of dutasteride administration does not suppress the expression of HIF-1 alpha, VEGF and microvessel density in human prostate tissue. Further clinical investigation with dutasteride including a larger, placebo-controlled study is warranted to establish the mechanism and duration of dutasteride.ko_KR
dc.language.isoenko_KR
dc.publisherTAYLOR & FRANCIS ASko_KR
dc.subjectDutasterideko_KR
dc.subjectvascularityko_KR
dc.subjectvascular endothelial growth factorko_KR
dc.subjecthypoxia-inducible factorko_KR
dc.subjectprostateko_KR
dc.titleEffect of dutasteride on the expression of hypoxia-inducible factor-1α, vascular endothelial growth factor and microvessel density in rat and human prostate tissueko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor구자현-
dc.contributor.AlternativeAuthor신정기-
dc.contributor.AlternativeAuthor조민철-
dc.contributor.AlternativeAuthor명재경-
dc.contributor.AlternativeAuthor문경철-
dc.contributor.AlternativeAuthor백재승-
dc.identifier.doi10.3109/00365590903337896-
dc.citation.journaltitleSCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY-
dc.description.citedreferenceHahn RG, 2007, BJU INT, V99, P587, DOI 10.1111/j.1464-410X.2006.06619.x-
dc.description.citedreferenceLekas AG, 2006, UROLOGY, V68, P436, DOI 10.1016/j.urology.2006.03.038-
dc.description.citedreferenceDonohue JF, 2005, BJU INT, V96, P1319, DOI 10.1111/j.1464-410X.2005.05849.x-
dc.description.citedreferenceBoccon-Gibod L, 2005, PROG UROL, V15, P1085-
dc.description.citedreferenceOzdal OL, 2005, PROSTATE CANCER P D, V8, P215, DOI 10.1038/sj.pcan.4500818-
dc.description.citedreferenceLund L, 2005, SCAND J UROL NEPHROL, V39, P160, DOI 10.1080/00365590510007694-
dc.description.citedreferenceCrea G, 2005, UROL INT, V74, P51, DOI 10.1159/000082709-
dc.description.citedreferenceAndriole GL, 2004, J UROLOGY, V172, P915, DOI 10.1097/01.ju.0000136430.37245.b9-
dc.description.citedreferencePark JW, 2004, J PHARMACOL SCI, V94, P221-
dc.description.citedreferenceDu ZX, 2003, CHINESE MED J-PEKING, V116, P1936-
dc.description.citedreferencePareek G, 2003, J UROLOGY, V169, P20, DOI 10.1097/01.ju.0000039923.75777.91-
dc.description.citedreferenceDonohue JF, 2002, J UROLOGY, V168, P2024, DOI 10.1097/01.ju.0000028607.29093.56-
dc.description.citedreferenceKearney MC, 2002, J UROLOGY, V167, P2489-
dc.description.citedreferenceHaggstrom S, 2002, SCAND J UROL NEPHROL, V36, P182-
dc.description.citedreferenceHochberg DA, 2002, J UROLOGY, V167, P1731-
dc.description.citedreferenceSandfeldt L, 2001, UROLOGY, V58, P972-
dc.description.citedreferenceTalks KL, 2000, AM J PATHOL, V157, P411-
dc.description.citedreferenceBurchardt M, 2000, PROSTATE, V43, P184-
dc.description.citedreferenceHagerty JA, 2000, UROLOGY, V55, P684-
dc.description.citedreferenceLekas E, 2000, BJU INT, V85, P962-
dc.description.citedreferenceFoley SJ, 2000, J UROLOGY, V163, P496-
dc.description.citedreferenceLevine AC, 1998, ENDOCRINOLOGY, V139, P4672-
dc.description.citedreferenceSieber PR, 1998, J UROLOGY, V159, P1232-
dc.description.citedreferenceKashif KM, 1998, PROSTATE CANCER P D, V1, P154-
dc.description.citedreferenceFranck-Lissbrant I, 1998, ENDOCRINOLOGY, V139, P451-
dc.description.citedreferenceMiller MI, 1998, UROLOGY, V51, P237-
dc.description.citedreferenceLekas E, 1997, UROL RES, V25, P309-
dc.description.citedreferenceCarlin BI, 1997, PROSTATE, V31, P180-
dc.description.citedreferencePUCHNER PJ, 1995, J UROLOGY, V154, P1779-
dc.description.citedreferenceMCCONNELL JD, 1992, J CLIN ENDOCR METAB, V74, P505-
dc.description.tc1-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share